AKU Stock Overview
Akumin Inc. provides outpatient diagnostic imaging services in the United States.
Price History & Performance
|Historical stock prices|
|Current Share Price||CA$1.90|
|52 Week High||CA$4.98|
|52 Week Low||CA$1.88|
|1 Month Change||-15.93%|
|3 Month Change||-9.52%|
|1 Year Change||-51.16%|
|3 Year Change||-56.42%|
|5 Year Change||n/a|
|Change since IPO||-61.22%|
Recent News & Updates
|AKU||CA Healthcare||CA Market|
Return vs Industry: AKU underperformed the Canadian Healthcare industry which returned -16.1% over the past year.
Return vs Market: AKU underperformed the Canadian Market which returned 17.4% over the past year.
|AKU Average Weekly Movement||9.2%|
|Healthcare Industry Average Movement||10.4%|
|Market Average Movement||9.8%|
|10% most volatile stocks in CA Market||17.4%|
|10% least volatile stocks in CA Market||3.7%|
Stable Share Price: AKU is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: AKU's weekly volatility (9%) has been stable over the past year.
About the Company
|n/a||n/a||Riadh Zine Zine-El-Abidine||https://www.akumin.com|
Akumin Inc. provides outpatient diagnostic imaging services in the United States. Its centers offer physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders and reduce unnecessary invasive procedures. The company provides various medical imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, digital radiography, fluoroscopy, and other diagnostic or interventional radiology procedures; and online medical bill payment services.
Akumin Fundamentals Summary
|AKU fundamental statistics|
Is AKU overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AKU income statement (TTM)|
|Cost of Revenue||US$223.16m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.16|
|Net Profit Margin||-4.50%|
How did AKU perform over the long term?See historical performance and comparison
Is Akumin undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: AKU (CA$1.9) is trading above our estimate of fair value (CA$1.82)
Significantly Below Fair Value: AKU is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: AKU is unprofitable, so we can't compare its PE Ratio to the Canadian Healthcare industry average.
PE vs Market: AKU is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AKU's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AKU is good value based on its PB Ratio (0.9x) compared to the CA Healthcare industry average (2.4x).
How is Akumin forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if AKU's forecast earnings growth is above the savings rate (1.6%).
Earnings vs Market: Insufficient data to determine if AKU's earnings are forecast to grow faster than the Canadian market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: AKU's revenue (40.3% per year) is forecast to grow faster than the Canadian market (5.5% per year).
High Growth Revenue: AKU's revenue (40.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AKU's Return on Equity is forecast to be high in 3 years time
How has Akumin performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AKU is currently unprofitable.
Growing Profit Margin: AKU is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AKU is unprofitable, and losses have increased over the past 5 years at a rate of 36.8% per year.
Accelerating Growth: Unable to compare AKU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AKU is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-10.6%).
Return on Equity
High ROE: AKU has a negative Return on Equity (-2.65%), as it is currently unprofitable.
How is Akumin's financial position?
Financial Position Analysis
Short Term Liabilities: AKU's short term assets ($206.1M) exceed its short term liabilities ($172.0M).
Long Term Liabilities: AKU's short term assets ($206.1M) do not cover its long term liabilities ($1.4B).
Debt to Equity History and Analysis
Debt Level: AKU's net debt to equity ratio (308.8%) is considered high.
Reducing Debt: AKU's debt to equity ratio has reduced from 441% to 324.1% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable AKU has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: AKU is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 51.2% per year.
What is Akumin current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AKU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AKU's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AKU's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AKU's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AKU's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Riadh Zine Zine-El-Abidine (49 yo)
Mr. Riadh Zine-El-Abidine also known as Riadh Zine, serves as Director at Peraso Inc. (formerly known as "Peraso Technologies Inc.") He has been Co-Chief Executive Officer at Akumin Inc. since September 1,...
CEO Compensation Analysis
Compensation vs Market: Riadh Zine's total compensation ($USD2.44M) is above average for companies of similar size in the Canadian market ($USD161.11K).
Compensation vs Earnings: Riadh Zine's compensation has been consistent with company performance over the past year.
Experienced Management: AKU's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Experienced Board: AKU's board of directors are considered experienced (4.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 26.9%.
Akumin Inc.'s employee growth, exchange listings and data sources
- Name: Akumin Inc.
- Ticker: AKU
- Exchange: TSX
- Founded: NaN
- Industry: Health Care Services
- Sector: Healthcare
- Implied Market Cap: CA$169.151m
- Shares outstanding: 89.03m
- Website: https://www.akumin.com
Number of Employees
- Akumin Inc.
- 8300 West Sunrise Boulevard
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/21 23:56|
|End of Day Share Price||2022/01/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.